Identification of Prognostic Urinary Biomarker for Acute Kidney Injury in Preterm Infants by Proteomics
NCT ID: NCT02743273
Last Updated: 2018-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
37 participants
OBSERVATIONAL
2015-10-31
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Because of several limitations of early detection of AKI, investigators are focused on identifying biomarkers that predict AKI before an increase serum creatinine level.
Investigators will collect urine from preterm infants before and after administrating ibuprofen for closing patent ductus arteriosus. To identify novel biomarkers, investigators will analyze urine by proteomics. To verify those biomarkers, investigators will use initial urine on the first day of life from preterm infants who diagnosed AKI within 7 days after birth without any risk factors for AKI and enrolled institutional bio-repository.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Renal Prognosis of Neonatal Acute Kidney Injury
NCT06731205
Acute Kidney Injury in Premature Infants
NCT00573079
Acute Kidney Injury in Neonates
NCT00572715
Outcomes of Neonatal Acute Kidney Injury In Premature Infants
NCT02375854
Acute Kidney Injury in Neonatal ICU in Assuit University
NCT07083284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known major congenital anomalies of the kidney and urinary tract
* Other genetic syndromes or medical conditions that preclude enrollment per judgement of the attending neonatologist
3 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Han-Suk Kim
Professor, Director of Neonatal Intensive Care Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Han-Suk Kim, MD, PhD.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Children's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1507-028-686
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.